In this issue:
Platinum-based chemotherapy may confer a benefit in CRPC patients with DNA repair mutations
OMNIVORE shows low responses to sequential ipilimumab in RCC nonresponsive to nivolumab
Neoadjuvant combination anti-PD-1 plus anti-CTLA-4 shows promise in muscle-invasive UC
TemPa finds no benefit to temsirolimus or pazopanib in highrisk advanced clear-cell RCC
Post-hoc analysis shows an effect modification of antibiotics on immune checkpoint inhibition in UC
Deferred cytoreductive nephrectomy elicits a survival advantage in newly diagnosed metastatic RCC
Cabazitaxel improves quality of life in pre-treated patients with CRPC
Cabozantinib plus nivolumab ± ipilimumab for genitourinary tumours
Poor outcomes following salvage lymph node dissection for nodal recurrence of prostate cancer
Tumour mutational burden and PD-L1 as predictors of response to nivolumab in bladder cancer
Please login below to download this issue (PDF)